Navigation Links
XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
Date:8/26/2008

r adverse cardiac events (MACE) were reported since the one-year analysis, and the incidence of late stent thrombosis for patients treated with Custom NX was zero percent. The CUSTOM I article published in EuroIntervention was recognized by the journal's editorial board as one of the six best papers submitted to the journal during the previous winter, and Lutz Buellesfeld, M.D., of the HELIOS Heart Center in Siegburg, Germany, received an award in conjunction with the publication after presenting it at the annual EuroPCR meeting in May.

The CUSTOM II trial was designed to evaluate the safety and efficacy of Custom NX for the treatment of long and multiple lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long-lesion arm, and 31 patients were enrolled in the two-lesion arm of the study. CUSTOM II enrolled one of the most difficult to treat patient populations ever studied in a DES trial. In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Twenty-six percent of the study participants were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. CUSTOM II's six-month clinical results have been sustained at one year. The target lesion revascularization rate remained constant at four percent, with no new MACE events, and no late stent thrombosis.

The EuroIntervention paper, titled "One year results of a new in-situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: result of the CUSTOM-II trial," can be accessed at: http://www.europcronline.com/eurointervention/15th_issue/37/.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to c
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
5. XTENT Announces First Quarter 2008 Financial Results
6. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
7. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
8. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
9. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
10. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
11. Genmab Announces Upcoming Ofatumumab Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Pa., Oct. 29 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today ... Credit Suisse Healthcare Conference to be held November 10-12, 2010 ... Fickenscher, Chief Financial Officer, is scheduled to present an overview ... ET on Thursday, November 11, 2010. To listen ...
... Calif., Oct. 28 VIVUS, Inc. (Nasdaq: ... Response Letter (CRL) from the U.S. Food and Drug ... the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The ... the NDA cannot be approved in its present form. ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... phone use on the road: studies , MONDAY, Sept. 28 ... difference in your teen,s safety once he or she gets ... firm rules, but do so in a helpful, supportive way, ... auto accident by half and decrease rates of drinking and ...
... 2009 Researchers at UT Southwestern Medical Center ... and lung cancer have become more prevalent among ... of anti-retroviral therapies in the mid-1990s. ... higher risk for so-called AIDS-defining malignancies cancers ...
... are invited to attend a gathering of the nation,s leading ... and develop programs that may help lower the nation,s costly ... held Oct. 8 and 9 in Arlington, Virginia, is a ... of Obstetricians and Gynecologists, the American Academy of Pediatrics, American ...
... approach to understanding how cells develop resistance to drugs has ... Anderson Cancer Center a New Innovator Award from the National ... M. D. Anderson,s Department of Systems Biology, will receive $1.5 ... NIH announced awards Thursday in three prestigious programs that fund ...
... Warning follows report that dosing instructions for liquid medication ... News) -- U.S. health officials have issued a public ... errors involving liquid Tamiflu for kids. , The alert, ... parents could give the wrong dose of Tamiflu to ...
... ... recognized in 42 states, gives consumers control over healthcare costs, saving time and money ... Philadelphia, ... out-patient physical therapy clinic with eight locations throughout the Philadelphia region, indicate that awareness ...
Cached Medicine News:Health News:Firm Parents Keep Teen Drivers Safe 2Health News:Firm Parents Keep Teen Drivers Safe 3Health News:Certain cancers more common among HIV patients than non-HIV patients 2Health News:Experts to review quality improvement programs to prevent preterm birth 2Health News:Experts to review quality improvement programs to prevent preterm birth 3Health News:M. D. Anderson scientist wins NIH New Innovator Award 2Health News:M. D. Anderson scientist wins NIH New Innovator Award 3Health News:FDA Issues Health Alert on Kids' Tamiflu Dosages 2Health News:FDA Issues Health Alert on Kids' Tamiflu Dosages 3Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 2Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 3
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: